Etelcalcetide set to become blockbuster in hyperparathyroidism market by 2025, says GlobalData
11 Jan 2017
The hyperparathyroidism therapeutics market is set to rise from $6.69 billion in 2015 to $8.04 billion by 2025, representing a compound annual growth rate of 1.8%, according to research and consulting firm GlobalData.
The company’s latest report states that major drivers of this growth, which will occur across the seven major markets of the US, France, Germany, Italy, Spain, the UK, and Japan, include the launch of Amgen’s first intravenous (IV) calcimimetic, Parsabiv (etelcalcetide), an increase in the global prevalence of the disease, the launch of Rayaldee (calcifediol ER) in the US in 2016, and increased use of new iron-based phosphate binders, Velphoro (sucroferric oxyhydroxide) and Auryxia (ferric citrate).
Michela J. McMullan, Ph.D., GlobalData’s Analyst covering Cardiovascular and Metabolic Disorders, explains: “Etelcalcetide may revolutionize the treatment of dialysis-dependent secondary hyperparathyroidism patients. The drug is vying for a robust launch into the hyperparathyroidism market by targeting a critical unmet need in the calcimimetic space: patient compliance.
“Etelcalcetide has been evaluated in several Phase III studies, which most prominently include superior results in a head-to-head study against the first-in-class calcimimetic, cinalcet, as well as encouraging results from two placebo-controlled studies; all of which instill confidence in etelcalcetide’s capability in treating secondary hyperparathyroidism dialysis patients. GlobalData believes it will take a critical market position, with projected sales soaring to $1.3 billion by 2025.”
Despite this, late-stage pipeline therapies in the hyperparathyroidism space do not address key unmet needs, which will stunt market growth as new therapies with suboptimal efficacy improvement struggle to enter a crowded space. Indeed, there remains a strong need for new-generation therapies to treat hyperphosphatemia with alternate mechanisms of action and enhanced efficacy and safety profiles, according to GlobalData.
McMullan continues: “Across the entire hyperparathyroidism therapeutic landscape, an improvement in compliance with the therapy is another major unmet need and concerns all drug classes from calcimimetics to phosphate binders and bisphosphates. In the primary hyperparathyroidism space, although parathyroidectomy provides a cure, endocrinologists have also emphasized the need for improved therapies to medically treat primary hyperparathyroidism patients who are not or cannot be managed with surgery.”
NOTES TO EDITORS
- Comments provided by Michela J. McMullan, Ph.D., GlobalData’s Analyst covering Cardiovascular and Metabolic Disorders.
- Information based on GlobalData’s report: OpportunityAnalyzer: Hyperparathyroidism – Opportunity Analysis and Forecasts to 2025.
- This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.
GlobalData is the premier source of actionable insight into the energy and healthcare industries.
With the combined expertise of more than 1,000 researchers, market analysts and consultants, we provide
high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase
For further details, please Contact Us.
Subscribe to our RSS Feed: